Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data [Yahoo! Finance]
Journey Medical Corporation (DERM)
Last journey medical corporation earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.dermira.com
Company Research
Source: Yahoo! Finance
Source: Pexels Earlier on December 10, Journey Medical Corp published results from a Phase 1 clinical trial, focusing on Emrosi's impact on microbial flora in healthy adults, in the Journal of Drugs in Dermatology. Emrosi is an FDA-approved oral medication used to treat skin conditions such as papules and pustules in adults. According to Journey Medical, the trial met all three primary endpoints. That is, there were no significant microbiome changes in skin; no notable antibiotic resistance to minocycline; and no major rise in opportunistic organisms compared to placebo. The data showed that Emrosi is well tolerated with no significant safety concerns. This aligns with its low-dose profile to minimize disruption to normal body flora and support safe, extended use in rosacea patients, Journey Medical noted. Claude Maraoui, Journey Medical's co-founder, president, and CEO, noted that this publication reinforces Emrosi's differentiated benefits as a low-dose option that avoids mea
Show less
Read more
Impact Snapshot
Event Time:
DERM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DERM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DERM alerts
High impacting Journey Medical Corporation news events
Weekly update
A roundup of the hottest topics
DERM
News
- Public companies account for 34% of Journey Medical Corporation's (NASDAQ:DERM) ownership, while institutions account for 33% [Yahoo! Finance]Yahoo! Finance
- Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyGlobeNewswire
- What Makes Journey Medical Corporation (DERM) a Good Investment? [Yahoo! Finance]Yahoo! Finance
- Journey Medical Corp (DERM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
DERM
Earnings
- 11/12/25 - Beat
DERM
Sec Filings
- 1/15/26 - Form S-3
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- DERM's page on the SEC website